| Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery (NCT04391049) | NRG Oncology | 2021-12-02 |
| Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers (NCT03935893) | Udai Kammula | 2019-12-03 |
| Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (NCT04116320) | Craig L Slingluff, Jr | 2019-11-21 |
| Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma (NCT03370276) | H. Lee Moffitt Cancer Center and Research Institute | 2017-12-20 |
| Using MC1R Genotype to Impact Melanoma Risk Behavior (NCT03509467) | H. Lee Moffitt Cancer Center and Research Institute | 2015-08-03 |
| Safety Study of SEA-CD40 in Cancer Patients (NCT02376699) | Seagen Inc. | 2015-02-28 |
| Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC) (NCT01721525) | Memorial Sloan Kettering Cancer Center | 2012-11-01 |
| Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer (NCT01384708) | Anandasabapathy, Sharmila, M.D. | 2010-08-01 |
| Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) (NCT01016769) | Memorial Sloan Kettering Cancer Center | 2009-11-01 |
| Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) (NCT00705016) | Merck KGaA, Darmstadt, Germany | 2008-10-01 |
| Zalutumumab in Non-curable Patients With SCCHN (NCT00542308) | Genmab | 2008-01-01 |
| Study of Sorafenib/Cetuximab in Head and Neck Cancer (NCT00815295) | Duke University | 2008-01-01 |
| Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (NCT00661427) | Memorial Sloan Kettering Cancer Center | 2007-11-01 |
| PET-CT for Squamous Cell Carcinoma (SCC) of the Neck Nodes Unknown Primary Malignancy (NCT00530283) | AHS Cancer Control Alberta | 2007-08-01 |
| Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer (NCT00485485) | M.D. Anderson Cancer Center | 2007-01-01 |
| Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer (NCT00401401) | Genmab | 2006-12-01 |
| Zalutumumab in Patients With Non-curable Head and Neck Cancer (NCT00382031) | Genmab | 2006-11-01 |
| The IRESSA Novel Head and Neck Chemotherapy Evaluation Study (NCT00255476) | AstraZeneca | 2004-02-01 |
| RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus (NCT00559351) | Ministry of Scientific Research and Information Technology, Poland | 2001-12-01 |
| A Study of Conventional 3D Radiation vs. Intensity-Modulated Radiation in Squamous Cell Cancer of the Head and Neck (NCT00363441) | Alberta Health services | |